drugset / Trial / NCT05443126
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.
Timeline
- Start
- 2022-09-30
- Primary completion
- 2027-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lunbotinib | Small molecule | — | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |